secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001628280-23-015804
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics enters $9M at-the-market equity offering with Oppenheimer
----------------------------------------------------------------------------

- Sales Agreement with Oppenheimer & Co. for up to $9,032,567 of common stock.
- Commission of 3.0% of gross proceeds; ATM offering under Rule 415.
- Shares sold under existing S-3 registration statement effective May 2, 2023.
- Company may suspend or terminate offering; no obligation to sell shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023015804/0001628280-23-015804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023015804/avtx-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer